Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.

Neuren has confirmed the primary goals for its double-blind, single Phase III pivotal trial of NNZ-2591 in treating PMS for ...

Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. The gold standard ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced solid tumours.

Emory University School of Medicine, US, has commenced subject enrolment for BioCardia’s Phase III CardiAMP HF II trial.

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.

A study by Larsen and colleagues has exemplified the role that HCs have in heightening depression risk in this group.